Stock Quote

The Big Picture for Virus Testing Stocks (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: CODX)

By: OTC

The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.

Even after we achieve the big goal of vaccine-induced herd immunity in the developed world, the pandemic will fester and mutate and hide out in the emerging world, continuously threatening from the shadows. While we appear on the verge of knocking out the scary version of this story – all but eradicating fatalities and hospitalizations where vaccines are widely available – the path will be difficult and longer than we may have hoped, and testing technology will remain key.

As such, investors may benefit from holding some exposure to stocks that have pure-play penetration in the virus testing technology space. With that in mind, we take a look at a few of the more interesting names in the testing marketplace, including: Fulgent Genetics Inc- (NASDAQ: FLGT), Allstar Health Brands Inc. (OTC US: ALST), and Co-Diagnostics, Inc. (NASDAQ: CODX).

 

Fulgent Genetics Inc. (NASDAQ: FLGT) provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes.

The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally.

Fulgent Genetics Inc. (NASDAQ: FLGT) most recently announced that the Company has extended its partnership with the New York City Department of Education (or “NYC DOE”) and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.

“We have been working with the teams in New York City over the last several weeks, which has been going extremely well. The ongoing success of our COVID-19 testing program is a major testament to the hard work of the teams in New York City and the Fulgent staff involved in the project,” said Brandon Perthuis, Fulgent’s Chief Commercial Officer.

The context for this announcement is a bit of a bid, with shares acting well over the past five days, up about 123% in that timeframe.

Fulgent Genetics Inc. (NASDAQ: FLGT) managed to rope in revenues totaling $101.7M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 883%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($74.9M against $57.7M).

 

Allstar Health Brands Inc. (OTC US: ALST) is perhaps the most interesting name here because it hasn’t priced in anything here and has a very interesting and unique angle on providing much-needed testing solutions.

This is a specialty pharmaceutical and nutritional supplements company. One of its core assets at this point is its partnership with TPT Global Tech, a technology and solutions company. The two companies are collaborating to create and distribute the QuickLAB module, a rapid testing solution for Covid-19. The two companies had already recently signed an agreement for Mexico and other Latin American countries through TPT Global Tech’s partner New Orbit Technologies. Now, they have signed an expanded agreement to bring QuickLAB distribution to Canada and US to add to the existing Non-Exclusive Distribution Agreement for Mexico and other Latin American countries.

Allstar Health Brands Inc. (OTC US: ALST) most recently announced an update on its diverse lines of business, including its latest efforts in the battle against the novel coronavirus SARS-CoV-2, the virus that causes COVID-19. AllStar Health Brands is seeing growing adoption and uptick in interest from current and new end-users for its diagnostic test kits for COVID-19, both for its antibody and its PCR tests, expecting an upward trend in sales in 2020 and 2021. Additionally, the Company is seeking to expand into the antigen test market.

“We’re unfortunately seeing rapid spreading of the coronavirus, with 42 states showing increases last week compared to prior week,” said Dr. Daniel Bagi, President of AllStar Health Brands. “Diagnosing the virus as quickly and as efficiently as possible will be a critical element to fighting this, particularly as a viable vaccine or therapeutic treatment appears to still be many months away from being broadly available to the general public.”

Allstar Health Brands Inc. (OTC US: ALST) generated sales of $178K, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 224.2% on the top line. ALST is surely a more speculative name on this list. But with the company’s recent expansion and partnership, it may also be the most underpriced.

 

Co-Diagnostics, Inc. (NASDAQ: CODX) develops, manufactures and markets a state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

The company intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Co-Diagnostics, Inc. (NASDAQ: CODX) recently announced that it has completed its submission to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) of its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test, a COVID-19 polymerase chain reaction (PCR) diagnostic designed to detect the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample.

“Our new extraction-free saliva test has been developed as part of our ongoing commitment to providing improved COVID-19 diagnostics for high-throughput laboratory settings, using technology with additional potential point-of-care applications,” said Dwight Egan, Co-Diagnostics CEO.

If you’re long this stock, then you’re liking how the stock has responded to the announcement. CODX shares have been moving higher over the past week overall, pushing about 22% to the upside on above average trading volume. Shares of the stock have powered higher over the past month, rallying roughly 58% in that time on strong overall action.

Co-Diagnostics Inc (NASDAQ: CODX) generated sales of $21.8M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -9.2% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($27.3M against $1.8M).

 

DISCLAIMER:  EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  EDM is NOT affiliated in any manner with any company mentioned herein.  EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  EDM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  EDM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed EDM has been compensated six thousand dollars for news coverage of the current press releases issued by Allstar Health Brands Inc by a third party.

EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.

 

 

 

 

 

 

Media Contact:

EDM Media LLC

Email: IR@EDM.Media

Office: 800-301-7883

EDM.Media

 

 

 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.